Author

Patrick Hall Lizotte

Dana-Farber Cancer InstituteORCID 0000-0001-9510-0036Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell signaling & trafficking· 2 Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Cloud Peter PaweletziD· 2 shared David Allen BarbieiD· 2 shared Ellis L. ReinherziD· 2 shared Jonathan S. Duke‐CohaniD· 2 shared Kemin TaniD· 2 shared Matthew J. LangiD· 2 shared Robert J. MallisiD· 2 shared Alexander GuseviD· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Cloud Peter PaweletzORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

ImmunologyThe Journal of ImmunologyPeer-reviewedJul 28, 2026

Atomistic TCR-ligand interactions shape memory T-cell differentiation

Aoi Akitsu, Kemin Tan, Robert J. Mallis…·Ellis L. Reinherz

The paper identifies how TCR-ligand interactions influence memory T-cell differentiation by analyzing clonotype-specific signaling and functional outcomes.

DOI 10.1093/jimmun/vkag141.1794

mousescRNA-seq

𝕏 PostBluesky

Cancer BiologyCell Death and DifferentiationPeer-reviewedDec 26, 2025

Drug tolerant persisters and immunotherapy persister cells exhibit cross-resistance and share common survival mechanisms

Maria Davern, Cole J. Turner, Daryl Griffin…·Anthony G. Letai

This study identifies common survival mechanisms between drug-tolerant persisters and immunotherapy persisters, showing they share reduced mitochondrial apoptotic sensitivity and cross-resistance to therapies.

7 citations

humanproteomics

𝕏 PostBluesky

ImmunologybioRxivPreprintNov 26, 2025

Cancers modulate p53 truncal neoantigen display to evade T cell detection

Koji Haratani, Bruce B. Reinhold, Jonathan S. Duke‐Cohan…·Ellis L. Reinherz

This study identifies that cancers limit p53 neoantigen display on MHC molecules, evading T cell detection through immune selection and ERAP1-mediated destruction.

DOI 10.1101/2025.11.26.690562

humanproteomics

𝕏 PostBluesky